US OptionsDetailed Quotes
ADCT250117P7500
- 5.25
- 0.000.00%
15min DelayClose Dec 31 16:00 ET
0.00High0.00Low
5.25Open5.25Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover364.82%IV-13.07%PremiumJan 17, 2025Expiry Date5.51Intrinsic Value100Multiplier16DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9106Delta0.1115Gamma0.36Leverage Ratio-0.0068Theta-0.0020Rho-0.33Eff Leverage0.0007Vega
ADC Therapeutics Stock Discussion
ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma
Monday, 30th December at 4:30 pm
LAUSANNE, Switzerland, Dec. 30, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced the completion of enrollment in LOTIS-5, the Phase 3 confirm...
NFA = not financial advice
RTH = regular trading hours
AH = after hours
LTB = left to borrow
CTB = cost to borrow
*I removed $AmpliTech Group (AMPG.US)$ because it just announced direct offering of $2M valued $1.6/shares. Now there are offerings where market defies it and continues to rally. We shall see tomorrow
$Nuburu (BURU.US)$ PR AH 12/11: Resolved compliance issue. Up AH. Low float. CTB...
ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
Wednesday, 11th December at 7:30 am
ZYNLONTA in combination with glofitamab demonstrated clinically meaningful benefit with 94% best ORR and 72% CR rate
Safety data show no dose-limiting toxicities (DLTs), no high-grade cytokine release syndrome (CRS) or high-g...
ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma
ADC Therapeutics announced updated data from two clinical trials evaluating ZYNLONTA®. In the first trial, ZYNLONTA combined with rituximab for relapsed/refractory follicular lymphoma showed a 97.4% overall response rate and 76.9% complete response rate, with 12-m...
This strategy relies heavily on technical analysis, with traders using charts, patterns, and indicators li...
PR Newswire· 6 mins ago
Company to host corporate update webcast to share results on December 11, 2024
LAUSANNE, Switzerland, Dec. 6, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), today announced that it will host a conference call and live webcast on Wednesday, December 11, 2024, at 8:30 a.m. EST to provide an update on preliminary data from the LOTIS-7Phase 1b open-label...
ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting
ADC Therapeutics (NYSE: ADCT) announced two investigator-initiated study abstracts on ZYNLONTA accepted for presentation at the 66th ASH Annual Meeting. The Phase 2 study combining ZYNLONTA with rituximab in relapsed/refractory follicular lymphomashowed a 97.1% overall response rate among 35 patients, with an 80% best complete metabolic respon...
No comment yet